血清维生素B12与老年2型糖尿病轻度认知功能障碍的关系

doi:10.3969/j.issn.1004-583X.2024.01.005

摘要/Abstract

摘要：

目的探讨血清维生素B₁₂(VB₁₂)水平与老年2型糖尿病(T2DM)合并轻度认知功能障碍(MCI)的相关性。方法收集2023年1月-2023年7月在抚顺市中心医院内分泌科收治入院的老年T2DM患者共120例,根据血清VB₁₂正常水平进行三等分,将患者分为A组(200≤VB₁₂<500 ng/L)36例,B组(500≤VB₁₂<800 ng/L)71例,C组(800≤VB₁₂<1100 ng/L)13例,采用简易蒙特利尔认知评估(MoCA)量表对各组进行认知功能评定比较。比较3组MCI患病率。用logistic回归分析维生素B₁₂的不同水平与MCI 的相对风险。结果 MCI发病率随VB₁₂水平的增高而降低。校正了性别、年龄、TC、HDL-C、LDL-C变量后,logistic回归结果显示,以C组为参照组,A组发生MCI的OR值(95% $C I$ )为6.121(1.161~32.265)。结论 200≤VB₁₂<500 ng/L是老年 T2DM 患者合并MCI的独立危险因素。

关键词: 糖尿病, 2型, 维生素B₁₂, 轻度认知功能障碍

Abstract:

Objective To investigate the correlation between serum vitamin B₁₂ (VB₁₂) level and mild cognitive impairment (MCI) in elderly patients with type 2 diabetes mellitus (T2DM). Methods A total of 120 elderly T2DM patients admitted to the Endocrinology Department of Fushun Central Hospital from January 2023 to July 2023 were collected. According to the tertiles of the measured serum VB₁₂, patients were divided into A group (200 ng/L≤VB₁₂<500 ng/L, $n$ =36), B group (500 ng/L≤VB₁₂<800 ng/L, $n$ =71), and C group (800 ng/L≤VB₁₂<1100 ng/L, $n$ =13). The cognitive function of patients was evaluated using the Simple Montreal Cognitive Assessment (MoCA) scale. The prevalence of MCI was compared among the three groups. Logistic regression was performed to analyze the relative risks for MCI in elderly T2DM patients with different levels of vitamin B₁₂. Results The incidence of MCI decreased with the increasing serum VB₁₂ level. After adjusting for gender, age, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), logistic regression results showed that with Group C as the reference group, the odds ratio ( $O R$ ) and corresponding 95% confidence interval ( $C I$ ) for MCI in Group A was 6.121 and 1.161-32.265, respectively. Conclusion Serum VB₁₂ ranging from 200 ng/L to 500 ng/L is an independent risk factor for MCI in elderly T2DM patients.

Key words: diabetes mellitus, type 2, vitamin B₁₂, mild cognitive impairment

中图分类号:

R587.1

张佳楠, 孙琳琳, 詹潇燕, 李冰. 血清维生素B₁₂与老年2型糖尿病轻度认知功能障碍的关系[J]. 临床荟萃, 2024, 39(1): 34-37.

Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus[J]. Clinical Focus, 2024, 39(1): 34-37.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2024.01.005

https://lchc.magtechjournal.com/CN/Y2024/V39/I1/34

图/表 3

表1 三组临床资料比较

Tab.1 Comparison of clinical data among three groups

项目	A组( $n$ =36)	B组( $n$ =71)	C组( $n$ =13)	$F$ / $H$ /χ²值	$P$ 值
年龄(岁)	71.5(68, 75.75)	70(67, 73)	68(67, 71)	6.773	0.034
男/女(例)	22/14	30/41	6/7	3.429	0.180
BMI(kg/m²)	24.64±2.81	24.23±3.18	25.46±3.92	0.894	0.412
收缩压(mmHg)	150.47±21.61	150.69±18.71	148.46±23.49	0.140	0.869
舒张压(mmHg)	87.06±13.60	84.17±10.10	85.77±10.18	0.418	0.660
吸烟史[例(%)]	19.4	22.5	23.1	3.970	0.137
饮酒史[例(%)]	22.2	21.1	7.7	1.881	0.390
糖尿病病程(年)	10(1.25, 19.25)	10(5, 20)	10(4, 17)	1.167	0.558
受教育年限(年)	8.39±2.91	8.55±2.735	9.69±2.43	1.131	0.326
FPG(mmol/L)	10.40±3.17	10.70±3.29	9.81±2.25	0.468	0.628
TC(mmol/L)	5.91±1.36	5.25±1.37	5.11±1.60	3.373	0.038
TG(mmol/L)	2.36(1.56, 3.19)	1.80(1.34, 2.75)	1.51(1.27, 3.32)	0.250	0.882
HDL-C(mmol/L)	1.00±0.21	1.03±0.24	1.22±0.39	4.154	0.018
LDL-C(mmol/L)	3.87±0.80	3.18±0.91	2.86±1.18	9.274	0.001
FINS(mIU/L)	11.64(8.32, 16.19)	11.28(8.21, 19.76)	11.61(8.88, 22.21)	0.180	0.914
FC-P(ng/ml)	2.05(1.49, 2.80)	2.18(1.65, 3.00)	2.41(1.19, 3.59)	1.052	0.591
HbA₁c(%)	9.40±1.82	9.46±2.08	10.21±1.36	0.920	0.401
MoCA(分)	23.11±2.84	24.92±1.74	26.85±1.99	17.000	0.001

表1 三组临床资料比较

Tab.1 Comparison of clinical data among three groups

项目	A组( $n$ =36)	B组( $n$ =71)	C组( $n$ =13)	$F$ / $H$ /χ²值	$P$ 值
年龄(岁)	71.5(68, 75.75)	70(67, 73)	68(67, 71)	6.773	0.034
男/女(例)	22/14	30/41	6/7	3.429	0.180
BMI(kg/m²)	24.64±2.81	24.23±3.18	25.46±3.92	0.894	0.412
收缩压(mmHg)	150.47±21.61	150.69±18.71	148.46±23.49	0.140	0.869
舒张压(mmHg)	87.06±13.60	84.17±10.10	85.77±10.18	0.418	0.660
吸烟史[例(%)]	19.4	22.5	23.1	3.970	0.137
饮酒史[例(%)]	22.2	21.1	7.7	1.881	0.390
糖尿病病程(年)	10(1.25, 19.25)	10(5, 20)	10(4, 17)	1.167	0.558
受教育年限(年)	8.39±2.91	8.55±2.735	9.69±2.43	1.131	0.326
FPG(mmol/L)	10.40±3.17	10.70±3.29	9.81±2.25	0.468	0.628
TC(mmol/L)	5.91±1.36	5.25±1.37	5.11±1.60	3.373	0.038
TG(mmol/L)	2.36(1.56, 3.19)	1.80(1.34, 2.75)	1.51(1.27, 3.32)	0.250	0.882
HDL-C(mmol/L)	1.00±0.21	1.03±0.24	1.22±0.39	4.154	0.018
LDL-C(mmol/L)	3.87±0.80	3.18±0.91	2.86±1.18	9.274	0.001
FINS(mIU/L)	11.64(8.32, 16.19)	11.28(8.21, 19.76)	11.61(8.88, 22.21)	0.180	0.914
FC-P(ng/ml)	2.05(1.49, 2.80)	2.18(1.65, 3.00)	2.41(1.19, 3.59)	1.052	0.591
HbA₁c(%)	9.40±1.82	9.46±2.08	10.21±1.36	0.920	0.401
MoCA(分)	23.11±2.84	24.92±1.74	26.85±1.99	17.000	0.001

图1 3组MCI患病率比较注:与C组比较,* P<0.05;与B组比较,# P<0.05。A组为200 ng/L≤VB12<500 ng/L;B组为500 ng/L≤VB12<800 ng/L;C组为800 ng/L≤VB12<1100 ng/L

Fig.1 Comparison of prevalence of MCI among three groups

表2 不同水平VB12对MCI的影响

Tab.2 Effects of different levels of VB12 on MCI

模型	组别	$O R$ (95% $C I$ )	$P$ 值
1	A	8.667(1.969~38.151)	0.004
	B	4.301(1.090~16.974)	0.037
	C	1	-
2	A	7.657(1.687~34.766)	0.008
	B	4.100(1.031~16.295)	0.045
	C	1	-
3	A	6.121(1.161~32.265)	0.033
	B	3.643(0.855~15.523)	0.081
	C	1	-

表2 不同水平VB12对MCI的影响

Tab.2 Effects of different levels of VB12 on MCI

模型	组别	$O R$ (95% $C I$ )	$P$ 值
1	A	8.667(1.969~38.151)	0.004
	B	4.301(1.090~16.974)	0.037
	C	1	-
2	A	7.657(1.687~34.766)	0.008
	B	4.100(1.031~16.295)	0.045
	C	1	-
3	A	6.121(1.161~32.265)	0.033
	B	3.643(0.855~15.523)	0.081
	C	1	-

参考文献 24

[1]	游月. 2型糖尿病合并轻度认知障碍患者不同认知领域与体力活动的相关性及影响因素研究[D]. 福建中医药大学, 2021.
[2]	糖尿病患者认知功能障碍专家共识[J]. 中华糖尿病杂志, 2021, 13(7): 678-694.
[3]	Exalto LG, Biessels GJ, Karter AJ, et al. Severe diabetic retinal disease and dementia risk in type 2 diabetes[J]. J Alzheimers Dis, 2014, 42 Suppl 3(3):S109-117. doi: 10.3233/JAD-132570 URL
[4]	Ringman JM, Medina LD, Rodriguez-Agudelo Y, et al. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease[J]. Curr Alzheimer Res, 2009, 6(4): 341-346. doi: 10.2174/156720509788929336 pmid: 19689233
[5]	Cacciapuoti F. Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease[J]. J Thromb Thrombolysis, 2013, 36(3): 258-262. doi: 10.1007/s11239-012-0856-x URL
[6]	Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer's disease?[J]. J Alzheimers Dis, 2010, 20(3): 765-775. doi: 10.3233/JAD-2010-091558 pmid: 20182021
[7]	Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the Framingham elderly population[J]. Am J Clin Nutr, 1994, 60(1): 2-11. doi: 10.1093/ajcn/60.1.2 pmid: 8017332
[8]	Vogiatzoglou A, Smith AD, Nurk E, et al. Cognitive function in an elderly population: Interaction between vitamin B₁₂ status, depression, and apolipoprotein E ε4: the Hordaland Homocysteine Study[J]. Psychosom Med, 2013, 75(1): 20-29. doi: 10.1097/PSY.0b013e3182761b6c pmid: 23213264
[9]	Stabler SP. Clinical practice. Vitamin B₁₂ deficiency[J]. N Engl J Med, 2013, 368(2): 149-160. doi: 10.1056/NEJMcp1113996 URL
[10]	Hin H, Clarke R, Sherliker P, et al. Clinical relevance of low serum vitamin B₁₂ concentrations in older people: The banbury B₁₂ study[J]. Age Ageing, 2006, 35(4): 416-422. doi: 10.1093/ageing/afl033 URL
[11]	Kim JM, Stewart R, Kim SW, et al. Changes in folate, vitamin B₁₂ and homocysteine associated with incident dementia[J]. J Neurol Neurosurg Psychiatry, 2008, 79(8): 864-868. doi: 10.1136/jnnp.2007.131482 pmid: 18252751
[12]	Diabetes mellitus. Report of a WHO study group[J]. World Health Organ Tech Rep Ser, 1985, 727: 1-113.
[13]	Kivipelto M, Helkala EL, Hänninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study[J]. Neurology, 2001, 56(12): 1683-1689. doi: 10.1212/wnl.56.12.1683 pmid: 11425934
[14]	Horton DK, Hynan LS, Lacritz LH, et al. An abbreviated montreal cognitive assessment (MoCA) for dementia screening[J]. Clin Neuropsychol, 2015, 29(4): 413-425. doi: 10.1080/13854046.2015.1043349 pmid: 25978540
[15]	Gilbert MP. Screening and treatment by the primary care provider of common diabetes complications[J]. Med Clin North Am, 2015, 99(1): 201-219. doi: 10.1016/j.mcna.2014.09.002 URL
[16]	Zilliox LA, Chadrasekaran K, Kwan JY, et al. Diabetes and cognitive impairment[J]. Curr Diab Rep, 2016, 16(9): 87.
[17]	Yu JT, Xu W, Tan CC, et al. Evidence-based prevention of Alzheimer's disease: Systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials[J]. J Neurol Neurosurg Psychiatry, 2020, 91(11): 1201-1209. doi: 10.1136/jnnp-2019-321913 URL
[18]	Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes[J]. Diabetes, 2002, 51(Suppl 1): S109-116. doi: 10.2337/diabetes.51.2007.S109 URL
[19]	血清叶酸、维生素B_(12)及同型半胱氨酸水平与老年人轻度认知功能障碍关系的病例对照研究[J]. 营养学报, 2019, 41(4): 343-346.
[20]	Wong CW. Vitamin B₁₂ deficiency in the elderly: Is it worth screening?[J]. Hong Kong Med J, 2015, 21(2): 155-164. doi: 10.12809/hkmj144383 pmid: 25756278
[21]	de Benoist B. Conclusions of a WHO technical consultation on folate and vitamin B₁₂ deficiencies[J]. Food Nutr Bull, 2008, 29(2 Suppl): S238-244. doi: 10.1177/15648265080292S129 pmid: 18709899
[22]	Wolters M, Ströhle A, Hahn A. Cobalamin: A critical vitamin in the elderly[J]. Prev Med, 2004, 39(6): 1256-1266. pmid: 15539065
[23]	Morris MS, Jacques PF, Rosenberg IH, et al. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification[J]. Am J Clin Nutr, 2007, 85(1): 193-200. doi: 10.1093/ajcn/85.1.193 pmid: 17209196
[24]	Jatoi S, Hafeez A, Riaz SU, et al. Low vitamin B₁₂ levels: An underestimated cause of minimal cognitive impairment and dementia[J]. Cureus, 2020, 12(2): e6976.

血清维生素B₁₂与老年2型糖尿病轻度认知功能障碍的关系

Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	琚盼雨, 杨富琦, 周兴建. 2型糖尿病患者TyG指数与甲状腺结节的关联性[J]. 临床荟萃, 2025, 40(4): 329-333.
[2]	胡松林, 邸雅, 刘灿章, 闫杰. 应用虚拟组织学血管内超声探讨血小板/淋巴细胞比值水平与冠心病合并2型糖尿病患者冠状动脉斑块特点的关系[J]. 临床荟萃, 2025, 40(2): 117-121.
[3]	史双伟, 饶小娟, 解丽然, 方一凡, 王姗姗. 甲状腺功能正常的2型糖尿病患者甲状腺激素敏感性与非酒精性脂肪肝的相关性[J]. 临床荟萃, 2025, 40(2): 133-137.
[4]	梁祎. 姜黄素对2型糖尿病患者炎症及氧化应激影响的meta分析[J]. 临床荟萃, 2024, 39(11): 974-979.
[5]	史莎莎, 任昊天, 宋丽菲, 李佳妮, 周岩, 张雁. 重症脑卒中患者肠内营养后高血糖管理的最佳证据总结[J]. 临床荟萃, 2024, 39(11): 1000-1006.
[6]	王静, 李彩格, 王婷, 刘子渤, 盖斌, 金杨瑜, 张力辉. 恩格列净与利拉鲁肽联合治疗肥胖/超重2型糖尿病患者的疗效及其对炎症因子的影响:一项前瞻、随机、开放、平行对照的临床研究[J]. 临床荟萃, 2024, 39(10): 909-914.
[7]	李佳文, 刘艳兰, 李瑶霜, 邱慧娜, 李芳, 毋帆, 林辰莹, 林静娜. 2型糖尿病患者TyG指数及其衍生指数与糖尿病肾病风险的相关性[J]. 临床荟萃, 2024, 39(10): 901-908.
[8]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[9]	熊璐, 郭莲. 2型糖尿病患者25(OH)D和SUA/SCr与合并非酒精性脂肪肝的相关性[J]. 临床荟萃, 2024, 39(8): 706-711.
[10]	张孟辉, 王新颖, 王树松, 帖彦清. 锌稳态在糖尿病及并发症中的作用[J]. 临床荟萃, 2024, 39(8): 758-762.
[11]	高姊璇, 刘建凤. 成人糖尿病分型及应用研究进展[J]. 临床荟萃, 2024, 39(7): 650-653.
[12]	岳江红, 王恒, 蔡钢, 张选明, 彭曦. 索格列净治疗2型糖尿病疗效和安全性的meta分析[J]. 临床荟萃, 2024, 39(7): 581-592.
[13]	杜斯娜, 李伟, 林雅静, 孙建国, 毛毛, 陈坚伟, 孙丹波, 毛玉山. 2型糖尿病胰岛素泵强化治疗后胰岛素剂量谱的分析及应用[J]. 临床荟萃, 2024, 39(7): 620-624.
[14]	孙辉, 刘海英, 任俊豪, 李锦霞. 欧洲人群体质指数与2型糖尿病因果关系的双向孟德尔随机化研究[J]. 临床荟萃, 2024, 39(4): 325-331.
[15]	王淑亮, 苏永峰. 肠道菌群在2型糖尿病中的研究进展[J]. 临床荟萃, 2024, 39(3): 274-278.